

Seeing is Believing! Putting the "SPARK" in You!



Ashley L. Anderson BSN, RN, CNOR and Deanna Wofford BSN, RN, CAPA

Clinical Issue

- In early 2018, Children's Hospital Los Angeles (CHLA) was granted surgical privileges to be a designated Vision Center for treating childhood blindness via gene therapy.
- This new procedure has the potential to improve multiple patient lives by restoring vision in patients with biallelic RPE65 mutation-associated retinal dystrophy.
- Administration of Luxturna (Sparks Therapeutics gene therapy) under a time sensitive strict protocol.
- First site to perform this FDA approved gene therapy.

Time is of the Essence

Pre-operative Check-in

 Pre-operative Evaluation

 Pharmacy Notified that patient is cleared for surgery
 Luxturna defrosting is initiated

 Patient in OR
 Delivery of Luxturna into the Operating Room


 Administration of Luxturna

Description of the Team

The Vision Center – Ophthalmology Surgery Department
Pharmacy Department
Opthamology Coordinator
Pre-operative Services
Intra-operative Services
Post-operative Services
Sterile Processing Department
Marketing & Communications Team

Implementation and Planning





Nursing Considerations

Pre-operative Phase

- Patient and Family Education
- Individualized Communication
- Coordination with Pharmacy

Baseline Assessment

Intra-operative Phase

- Appropriate Supplies and Equipment
- Confirmation of Defrosted Drug
- Individualized Communication
- Time Management of Drug Administration Post-operative Phase

Individualized Communication

- Appropriate Post on Positionin
- Appropriate Post-op Positioning
- Home Care Instructions

*PALS and ACLS personnel available at all phases

Acknowledgments

A special thanks goes to surgery service line director, Hazel Gould, and peri-operative managers, Nancy Bridges, Allison Fell, and Leticia Boutros, for supporting interdisciplinary collaboration of this project. Thank you to the ophthalmology team for coordinating initial planning meetings. Finally, thank you to Sandy Hall for your professional guidance in the creation of this professional poster.

References

Guttman Krader, C. (2018). Retinal Drug Launch: New era of gene therapy. Ophthalmology Times, 43(3), 1-17.

Rothrock, J. C., & McEwen, D. R. (2015). Alexander's care of the patient in surgery (15th edition.). St. Louis, Missouri: Elsevier/Mosby.

Spark Therapeutics (n.d.) Our commitment to inherited retinal disease (IRD). Retrieved from http://sparktx.com